First subjects dosed in Phase-1 clinical trial of Cognitive Disorder drug SUVN-I6107: Suven Life Sciences
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-01-09 07:00 GMT | Update On 2025-01-09 07:01 GMT
Advertisement
Hyderabad: Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, has announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of Investigational New Drug (IND) and issue of Study May Proceed letter.
SUVN-I6107 is the fifth internally discovered compound to advance into clinical trials and an addition to Suven’s extensive, fully-owned pipeline of oral small molecules to address large disease populations with significant unmet need in neuroscience.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.